Literature DB >> 33529583

Normal- and Low-Luminance Automated Quantitative Contrast Sensitivity Assessment in Eyes With Age-Related Macular Degeneration.

William C Ou1, Luis Andres Lesmes2, Abigail H Christie1, Renee A Denlar1, Karl G Csaky3.   

Abstract

PURPOSE: To assess the effectiveness of an active learning approach to measuring the contrast sensitivity function (CSF) in patients with various degrees of dry age-related macular degeneration (AMD) under multiple luminance conditions.
DESIGN: Cross-sectional study.
METHODS: Patients with AMD (26 intermediate AMD, 19 AMD with subretinal drusenoid deposits [SDD], 20 geographic atrophy [GA]) and 23 age-matched controls were tested with the Manifold Contrast Vision Meter (Adaptive Sensory Technology) and the qCSF algorithm, which applies active learning to estimate a model of the CSF's global shape. Testing was performed under conditions of standard and low luminance. For each AMD severity, the area under log CSF (AULCSF) and contrast sensitivities at individual spatial frequencies were calculated for analysis. Low-luminance deficits (LLDs) for visual acuity (VA) and AULCSF were calculated as the difference between standard and low luminance values.
RESULTS: Progressive decreases in AULCSF were observed as disease severity increased. For standard luminance, pairwise comparisons revealed significant differences between control/intermediate AMD (P < .0005), control/SDD (P < .0005), control/GA (P < .0005), and intermediate AMD/GA (P < .005). Similarly, for low luminance, pairwise comparisons revealed significant differences between the controls and each disease group (all P < .0005), in addition to significant differences between intermediate AMD/SDD (P < .005), and intermediate AMD/GA (P < .005). No correlations were found between LLD VA and LLD AULCSF in any AMD groups.
CONCLUSIONS: Contrast sensitivity measured via qCSF under both standard- and low-luminance conditions correlates with advancing stages of dry AMD. The interaction between luminance and contrast sensitivity appears to reflect a different aspect of visual function than the interaction between luminance and VA.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Year:  2021        PMID: 33529583     DOI: 10.1016/j.ajo.2021.01.017

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  5 in total

1.  Structure-function association between contrast sensitivity and retinal thickness (total, regional, and individual retinal layer) in patients with idiopathic epiretinal membrane.

Authors:  Rebecca Zeng; Filippos Vingopoulos; Mengyu Wang; Augustine Bannerman; Hannah E Wescott; Grace Baldwin; Raviv Katz; Thomas Koch; Tobias Elze; Leo A Kim; Demetrios G Vavvas; Deeba Husain; John B Miller
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-09-23       Impact factor: 3.535

2.  Contrast Sensitivity Deficits and Its Structural Correlates in Fuchs Uveitis Syndrome.

Authors:  Fang-Yue Zhou; Yi-Sha Li; Xingneng Guo; Xiutong Shi; Ke Wu; Jing-Wei Zheng; Xia-Xin Li; Jiaqing Wu; Ruru Liu; Ma-Li Dai; Xiu-Feng Huang; Fang Hou; Dan Lin; Yu-Qin Wang
Journal:  Front Med (Lausanne)       Date:  2022-05-19

3.  Hierarchical Bayesian modeling of contrast sensitivity functions in a within-subject design.

Authors:  Yukai Zhao; Luis Andres Lesmes; Fang Hou; Zhong-Lin Lu
Journal:  J Vis       Date:  2021-11-01       Impact factor: 2.240

4.  Comparison of two different contrast sensitivity devices in young adults with normal visual acuity with or without refractive surgery.

Authors:  Hyunjean Jung; Sung Uk Han; Sangyeop Kim; Hyunmin Ahn; Ikhyun Jun; Hyung Keun Lee; Kyoung Yul Seo; Tae-Im Kim
Journal:  Sci Rep       Date:  2022-07-28       Impact factor: 4.996

5.  Mental health and visual acuity in patients with age-related macular degeneration.

Authors:  Cheryl N Fonteh; Marc T Mathias; Naresh Mandava; Niranjan Manoharan; Anne M Lynch; Roxanne Navo; Jennifer L Patnaik
Journal:  BMC Ophthalmol       Date:  2022-10-02       Impact factor: 2.086

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.